Santhera Receives Positive NICE Final Guidance for AGAMREE^® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

Santhera Pharmaceuticals announces that the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance that recommends AGAMREE® (vamorolone) for use in the National Health Service in England, Wales, and Northern Ireland for the treatment of Duchenne muscular dystrophy in patients 4 years of age and older.